March 15, 2022
Life Sciences
  • Biogen Inc. will gain full authority over Aduhelm, its controversial Alzheimer’s disease drug, after partner Eisai Co. gave up its rights to make regulatory or sales decisions and share in the profits for the treatment. The drug’s outlook has weakened since it was approved in June. A Biogen executive said the deal, which will grant Eisai royalties for the drug from next year, will give Biogen more flexibility to react to market forces such as a pending federal decision around Medicare coverage. (Article here)